Advanced

Survival in cancer patients hospitalized for inflammatory bowel disease in Sweden.

Shu, Xiaochen LU ; Ji, Jianguang LU ; Sundquist, Jan LU ; Sundquist, Kristina LU and Hemminki, Kari LU (2011) In Inflammatory Bowel Diseases 17. p.816-822
Abstract
BACKGROUND:: The increased cancer risk among patients diagnosed with inflammatory bowel disease (IBD) is well reported, whereas studies regarding the cancer prognosis with IBD have shown conflicting results. We aimed at assessing and quantifying the cause-specific and overall mortality among cancer patients with IBD compared to those without IBD. METHODS:: The population-based Swedish registers were used to identify cancer patients diagnosed with or without IBD. We used a Cox regression model to estimate hazard ratios (HRs) for cause-specific and overall mortality, showing the probability of death in the study group compared to the reference. RESULTS:: A total of 2462 cancer patients with IBD and 1,011,894 cancer patients without IBD were... (More)
BACKGROUND:: The increased cancer risk among patients diagnosed with inflammatory bowel disease (IBD) is well reported, whereas studies regarding the cancer prognosis with IBD have shown conflicting results. We aimed at assessing and quantifying the cause-specific and overall mortality among cancer patients with IBD compared to those without IBD. METHODS:: The population-based Swedish registers were used to identify cancer patients diagnosed with or without IBD. We used a Cox regression model to estimate hazard ratios (HRs) for cause-specific and overall mortality, showing the probability of death in the study group compared to the reference. RESULTS:: A total of 2462 cancer patients with IBD and 1,011,894 cancer patients without IBD were ascertained from 1964 to 2006, showing a significant survival disparity (overall HR, 1.26; 95% confidence interval [CI]: 1.20-1.33 versus cause-specific HR, 1.22; 95% CI: 1.15-1.29). Although worse overall cancer mortality with IBD was widely observed, the worse cause-specific mortality was only confined to colorectal cancer (CRC). There was no difference in TNM staging among cancer patients with or without IBD. Stratified analyses showed that a worse prognosis was more pronounced in younger patients (<60 years) and in men. Discordant malignant neoplasms and cardiovascular diseases were noted to be associated with increased mortality in the study group. CONCLUSIONS:: Previously diagnosed IBD worsens the prognosis of cancers, especially for CRC. The more pronounced effect was noted among younger patients and in men. The underlying mechanisms warrant further investigation. (Inflamm Bowel Dis 2010). (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Inflammatory Bowel Diseases
volume
17
pages
816 - 822
publisher
John Wiley & Sons
external identifiers
  • wos:000287893500015
  • pmid:20645319
  • scopus:79951605275
ISSN
1536-4844
DOI
10.1002/ibd.21380
language
English
LU publication?
yes
id
466b4dda-65ec-495f-b2b3-ca4209eaa7d0 (old id 1644740)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20645319?dopt=Abstract
date added to LUP
2010-08-03 10:05:43
date last changed
2017-04-09 04:31:11
@article{466b4dda-65ec-495f-b2b3-ca4209eaa7d0,
  abstract     = {BACKGROUND:: The increased cancer risk among patients diagnosed with inflammatory bowel disease (IBD) is well reported, whereas studies regarding the cancer prognosis with IBD have shown conflicting results. We aimed at assessing and quantifying the cause-specific and overall mortality among cancer patients with IBD compared to those without IBD. METHODS:: The population-based Swedish registers were used to identify cancer patients diagnosed with or without IBD. We used a Cox regression model to estimate hazard ratios (HRs) for cause-specific and overall mortality, showing the probability of death in the study group compared to the reference. RESULTS:: A total of 2462 cancer patients with IBD and 1,011,894 cancer patients without IBD were ascertained from 1964 to 2006, showing a significant survival disparity (overall HR, 1.26; 95% confidence interval [CI]: 1.20-1.33 versus cause-specific HR, 1.22; 95% CI: 1.15-1.29). Although worse overall cancer mortality with IBD was widely observed, the worse cause-specific mortality was only confined to colorectal cancer (CRC). There was no difference in TNM staging among cancer patients with or without IBD. Stratified analyses showed that a worse prognosis was more pronounced in younger patients (&lt;60 years) and in men. Discordant malignant neoplasms and cardiovascular diseases were noted to be associated with increased mortality in the study group. CONCLUSIONS:: Previously diagnosed IBD worsens the prognosis of cancers, especially for CRC. The more pronounced effect was noted among younger patients and in men. The underlying mechanisms warrant further investigation. (Inflamm Bowel Dis 2010).},
  author       = {Shu, Xiaochen and Ji, Jianguang and Sundquist, Jan and Sundquist, Kristina and Hemminki, Kari},
  issn         = {1536-4844},
  language     = {eng},
  pages        = {816--822},
  publisher    = {John Wiley & Sons},
  series       = {Inflammatory Bowel Diseases},
  title        = {Survival in cancer patients hospitalized for inflammatory bowel disease in Sweden.},
  url          = {http://dx.doi.org/10.1002/ibd.21380},
  volume       = {17},
  year         = {2011},
}